• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now

    10/31/23 7:00:00 AM ET
    $AGBA
    $AMPE
    $CING
    $COCH
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGBA alert in real time by email

    MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 64th Emerging Growth Conference on November 1st and 2nd, 2023.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the conference here.

    Submit Questions for any of the presenting companies to:

    Questions@EmergingGrowth.com

    For updates, follow us on Twitter

    Day 1

    November 1, 2023

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 - 9:35

    AGBA Group Holding Limited (NASDAQ:AGBA)

    Keynote speaker: Mr. Wing-Fai Ng, Group President of AGBA Group

    9:40 - 10:10

    Battery Mineral Resources Corp., (OTCQB:BTRMF) (TSXV:BMR)

    KeKeynote speaker: Martin Kostuik, President / CEO

    10:15 - 10:45

    Envoy Medical, Inc. (NASDAQ:COCH)

    Keynote speaker: Brent Lucas, CEO & David R. Wells, CFO

    10:50 - 11:20

    Houston Natural Resources Corp. (OTC:HNRC)

    Keynote speaker: Frank Kristan, Chairman & CEO

    11:25 - 11:55

    Electronic Servitor Publication Network Inc. (OTCQB:XESP)

    Keynote speaker: Peter Hager, President / CEO

    12:00 - 12:30

    Jaguar Health, Inc. (NASDAQ:JAGX)

    Keynote speaker: Lisa A. Conte, Founder, CEO, President & Director

    12:35 - 1:05

    Ocean Biomedical, Inc. (NASDAQ:OCEA)

    Keynote speakers:

    Dr. Chirinjeev Kathuria, Co-founder / Chairman,

    Elizebeth Ng, CEO,

    Dr. Jonathan Kurtis, Scientific Co-founder & Director of the MD/PhD program Brown University,

    Gurinder Kalra, CFO,

    Daniel Behr, EVP of Academic Partnerships,

    Dr. Inderjote Kathuria, Chief Strategy Officer

    1:10 - 1:40

    GPO Plus, Inc. (OTCQB:GPOX)

    Keynote speaker: Brett Pojunis, President / CEO

    Postponed to December 6

    Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP)

    Keynote speaker: David Mehalick, President / CEO

    2:20 - 2:50

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO & Harry M. Lander, Ph.D. Senior Scientific Consultant

    2:55 - 3:05

    Renforth Resources, Inc. (OTCQB:RFHRF) (CSE:RFR)

    Keynote speaker: Nicole Brewster, President & CEO

    3:10 - 3:20

    Ideal Power (NASDAQ:IPWR)

    Keynote speaker: Dan Brdar, President / CEO, & Tim Burns, CFO

    3:25 - 3:35

    Steppe Gold, Ltd. (OTCQX:STPGF) (TSX:STGO)

    Keynote speakers: Aneel Singh, Exec. VP & Director

    3:40 - 3:50

    NeuroMetrix, Inc. (NASDAQ:NURO)

    Keynote speaker: Dr. Shai Gozani, CEO & Thomas Higgins, CFO

    3:55 - 4:05

    RedCloud Technologies, a Private Company

    Keynote speaker: Justin Floyd, CEO

    Day 2

    November 2, 2023

    10:00

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:35

    Introduction

    10:15 - 10:45

    Sonim Technologies, Inc. (NASDAQ:SONM)

    Keynote speaker: Hao Liu, CEO

    10:50 - 11:20

    Quantum Computing Inc., (NASDAQ:QUBT)

    Keynote speakers: Robert Liscouski, CEO, & Chris Boehmler, CFO

    11:25 - 11:55

    Gold Terra Resource Corp. (OTCQX:YGTFF) (TSXV:YGT)

    Keynote speaker: Gerald Sylvain Panneton, CEO

    12:00 - 12:30

    Independence Contract Drilling, Inc. (NYSE:ICD)

    Keynote speaker: Anthony Gallegos, President / CEO & Director

    12:35 - 1:05

    BioHarvest Sciences Inc. (OTCQB:CNVCF) (CSE:BHSC)

    Keynote speaker: Ilan Sobel, CEO

    1:10 - 1:40

    Ampio Pharmaceuticals, Inc. (NYSE:AMPE)

    Keynote speaker: Michael Martino, CEO & Director

    1:45 - 2:15

    Medicus Pharma Ltd. (TSXV:MDCX)

    Keynote speaker: Carolyn Bonner, President

    Postponed to December 6

    Cingulate Inc. (NASDAQ:CING)

    Keynote speaker: Shane Schaffer, CEO

    2:55 - 3:05

    Loop Industries, Inc. (NASDAQ:LOOP)

    Keynote speaker: Kevin C. O'Dowd, VP Communications

    3:10 - 3:20

    Theriva Biologics Inc., (NYSE:TOVX)

    Keynote speaker: Dr. Manel Cascallo', General Director

    3:25 - 3:35

    Alpha Tau Medical, Inc. (NASDAQ:DRTS)

    eynote speaker: Raphi Levy, CFO

    3:55 - 4:05

    GeoVax Labs, Inc. (NASDAQ:GOVX)

    Keynote speaker: David Dodd, Chairman, President / CEO

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the conference here.

    Submit Questions for any of the presenting companies to:

    Questions@EmergingGrowth.com

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: Conference@EmergingGrowth.com



    Primary Logo

    Get the next $AGBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGBA
    $AMPE
    $CING
    $COCH

    CompanyDatePrice TargetRatingAnalyst
    Alpha Tau Medical Ltd.
    $DRTS
    5/28/2026$15.00Overweight
    Barclays
    Quantum Computing Inc.
    $QUBT
    4/20/2026$20.00Outperform
    Northland Capital
    Envoy Medical Inc.
    $COCH
    3/31/2026$2.50Buy
    H.C. Wainwright
    Alpha Tau Medical Ltd.
    $DRTS
    3/4/2026$5.00Overweight → Neutral
    Piper Sandler
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Quantum Computing Inc.
    $QUBT
    1/15/2026$22.00Buy
    Rosenblatt
    Quantum Computing Inc.
    $QUBT
    12/17/2025$12.00Neutral
    Wedbush
    Quantum Computing Inc.
    $QUBT
    9/18/2025$24.00Buy
    Lake Street
    More analyst ratings

    $AGBA
    $AMPE
    $CING
    $COCH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial

    White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company continues to build momentum with the hearing industry."Envoy Medical continues to demonstrate its ability to execute," said Brent Lucas, Chief Executive Officer of Envoy Medical. "Each milestone achieved brings us one bi

    7/21/26 9:17:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

    - Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) - - Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared to just 19% ORR from historical benchmarks for pembrolizumab monotherapy in this setting - - Median overall survival of 18.2 months and median progression-free survival of 5.4 months compare favorab

    7/21/26 8:30:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

    - The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the Banner MD Anderson team, led by Dr. Samuels, has also treated multiple patients - - Immunocompromised patients face dramatically higher rates of cSCC, the second most common type of skin cancer in the U.S., than the general population - as much as 65- to 100-fold among organ transplant recipients specifically - - For many patients in this population, the general treatment options for recurrent cSCC can actually cause real harm: checkpoint inhibitor immunotherapy, the standard option for the g

    7/15/26 8:30:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $AGBA
    $AMPE
    $CING
    $COCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Schaffer Shane J.

    4 - Cingulate Inc. (0001862150) (Issuer)

    7/20/26 7:37:49 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP & Chief Commercial Officer Downey Bryan Wade

    4 - Cingulate Inc. (0001862150) (Issuer)

    7/20/26 7:35:39 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lawrence Bryan Jay

    4 - Cingulate Inc. (0001862150) (Issuer)

    7/20/26 7:32:30 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AMPE
    $CING
    $COCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hargroves Thomas Jeffrey bought $490,271 worth of shares (97,276 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    6/8/26 7:02:03 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Turmelle Michael C bought $39,900 worth of shares (5,250 units at $7.60), increasing direct ownership by 7% to 83,582 units (SEC Form 4)

    4 - Ideal Power Inc. (0001507957) (Issuer)

    6/1/26 4:01:55 PM ET
    $IPWR
    Semiconductors
    Technology

    President and CEO Somo David M bought $250,000 worth of shares (90,909 units at $2.75), increasing direct ownership by 37% to 338,347 units (SEC Form 4)

    4 - Ideal Power Inc. (0001507957) (Issuer)

    2/26/26 8:49:32 AM ET
    $IPWR
    Semiconductors
    Technology

    $AGBA
    $AMPE
    $CING
    $COCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Alpha Tau with a new price target

    Barclays initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $15.00

    5/28/26 8:55:01 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Northland Capital initiated coverage on Quantum Computing with a new price target

    Northland Capital initiated coverage of Quantum Computing with a rating of Outperform and set a new price target of $20.00

    4/20/26 8:28:07 AM ET
    $QUBT
    Computer Software: Prepackaged Software
    Technology

    H.C. Wainwright initiated coverage on Envoy Medical with a new price target

    H.C. Wainwright initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $2.50

    3/31/26 8:12:03 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $AGBA
    $AMPE
    $CING
    $COCH
    SEC Filings

    View All

    SEC Form 6-K filed by Alpha Tau Medical Ltd.

    6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

    7/21/26 8:30:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Ideal Power Inc.

    EFFECT - Ideal Power Inc. (0001507957) (Filer)

    7/20/26 12:15:16 AM ET
    $IPWR
    Semiconductors
    Technology

    SEC Form S-1 filed by Jaguar Health Inc.

    S-1 - Jaguar Health, Inc. (0001585608) (Filer)

    7/15/26 5:37:04 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AMPE
    $CING
    $COCH
    Leadership Updates

    Live Leadership Updates

    View All

    Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

    Significant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa

    6/25/26 11:35:00 AM ET
    $ORMP
    $DRTS
    $SCLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    Envoy Medical Appoints Chas McKhann to Board of Directors

    Proven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareholder Value Leading to over $3.4 Billion in Successful ExitsWhite Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced the appointment of Chas McKhann, a seasoned medical technology executive with documented success, to its Board of Directors.Mr. McKhann is a well-known and respected med tech leader with extensive experience creating and executing commercialization plans that have scaled into high-growth companies creating significant shareholder valu

    4/16/26 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

    BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Mr. Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on M

    3/11/26 7:30:00 AM ET
    $MYNZ
    $QUBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $AGBA
    $AMPE
    $CING
    $COCH
    Financials

    Live finance-specific insights

    View All

    DNA X, Inc. Reports First Quarter 2026 Financial Results

    Closed sale of the Company's mobile device assets to NEXA in January 2026Completed the transfer of the operations of the phone and hotspot business to NEXAFocused on enhancing the DNA X trading platform to prepare the platform for its initial growth phaseSan Diego, California--(Newsfile Corp. - May 20, 2026) - DNA X, Inc. (NASDAQ:SONM), a provider of cryptocurrency trading services, today announced its financial results for the first quarter ended March 31, 2026. The company operates the DNA X AI trading platform business, and expects to launch an enhanced version to the public later this year. The platform is designed to harness advanced AI and machine learning technologies to automate inte

    5/20/26 5:00:00 PM ET
    $SONM
    Telecommunications Equipment
    Utilities

    Ideal Power Reports First Quarter 2026 Financial Results

    AUSTIN, Texas, May 14, 2026 /PRNewswire/ -- Ideal Power Inc. (NASDAQ:IPWR) ("Ideal Power," the "Company," "we," "us" or "our"), developer and provider of its innovative and widely patented B-TRAN® bidirectional semiconductor power switch, reports results for its first quarter ended March 31, 2026."We had a strong start to the year as we initiated two additional projects with our lead Asia customer, signed a letter of intent with an industry partner to co-develop a B-TRAN®-enabled prototype for evaluation by a U.S. hyperscaler supporting the new NVIDIA Rubin Ultra 800V DC AI data center power distribution architecture, advanced Stellantis deliverables on schedule, and engaged on new opportuni

    5/14/26 9:20:00 AM ET
    $IPWR
    Semiconductors
    Technology

    Quantum Computing Inc. Reports First Quarter 2026 Financial Results

    Q1 revenue increases to $3.7 million from $39 thousand in Q1 '25Company completes two strategic acquisitions advancing its product roadmap to deliver practical quantum and photonics solutionsEnds quarter with $1.4 billion in cash, cash equivalents and investmentsHOBOKEN, N.J., May 11, 2026 /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (NASDAQ:QUBT), a quantum optics and integrated photonics company, today released financial results for the three months ended March 31, 2026.Dr. Yuping Huang, Chief Executive Officer of QCi, commented, "QCi made significant operational progress in the first quarter of 2026, furthering our mission of delivering accessible, scalable, and afforda

    5/11/26 4:05:00 PM ET
    $QUBT
    Computer Software: Prepackaged Software
    Technology

    $AGBA
    $AMPE
    $CING
    $COCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

    SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    11/14/24 5:10:48 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Coeptis Therapeutics Holdings Inc.

    SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    11/14/24 3:59:49 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care